What will it mean to be a global biotechnology entity?  As 2003 has brought continued market value and financing frustrations for the biotechnology sector, organisations are becoming more global as normal course.  Three key factors will continue to drive this phenomenon:

1.The restructuring, consolidation and reorganisation of global pharmaceutical and medical products companies;

2.The truly global possibilities of financing and venture capital resources;

3.The potential impact of global regulatory considerations.

The 2003 update to the Borderless Biotechnology report will explore these three premises and provide a current look at key global biotechnology markets.